Literature DB >> 30153442

Canonical transient receptor potential 3 channels in atrial fibrillation.

Lu Han1, Juxiang Li2.   

Abstract

The pathogenesis of atrial fibrillation (AF) is largely dependent on structural remodeling and electrical reconfiguration, which in turn drive localized fibrosis. Canonical transient receptor potential 3 (TRPC3) channel is indispensable regulator of fibrosis development, promoting fibroblasts to transition into myofibroblasts via intracellular Ca2+ overload. TRPC3 is a non-voltage gated, non-selective cation channel that regulates the permeability of the cell to Ca2+. When subjected to various external physical and chemical stimuli, such as angiotensin II (AngII), mechanical stretch, hypoxia, or oxidative stress, TRPC3 coordinates with downstream signal transduction pathways to alter gene expression and thereby regulate a number of distinct pathological patterns and mechanisms. This review will focus on how TRPC3 affects AF pathogenesis by exploring the underlying mechanisms governing fibrosis associated with particular signaling proteins, ultimately highlighting the characteristics of TPRC3 that mark it as a novel therapeutic target for AF alleviation.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Ca(2+) influx; Canonical transient receptor potential receptor 3; Cardiac remodeling

Mesh:

Substances:

Year:  2018        PMID: 30153442     DOI: 10.1016/j.ejphar.2018.08.030

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  TRPC channels: Structure, function, regulation and recent advances in small molecular probes.

Authors:  Hongbo Wang; Xiaoding Cheng; Jinbin Tian; Yuling Xiao; Tian Tian; Fuchun Xu; Xuechuan Hong; Michael X Zhu
Journal:  Pharmacol Ther       Date:  2020-01-28       Impact factor: 12.310

2.  Identification of microRNAs enriched in exosomes in human pericardial fluid of patients with atrial fibrillation based on bioinformatic analysis.

Authors:  Langsha Liu; Yubin Chen; Jie Shu; Can-E Tang; Ying Jiang; Fanyan Luo
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

3.  Angiotensin-II-Evoked Ca2+ Entry in Murine Cardiac Fibroblasts Does Not Depend on TRPC Channels.

Authors:  Juan E Camacho Londoño; André Marx; Axel E Kraft; Alexander Schürger; Christin Richter; Alexander Dietrich; Peter Lipp; Lutz Birnbaumer; Marc Freichel
Journal:  Cells       Date:  2020-01-29       Impact factor: 6.600

4.  Using Network Pharmacology to Explore Potential Treatment Mechanism for Coronary Heart Disease Using Chuanxiong and Jiangxiang Essential Oils in Jingzhi Guanxin Prescriptions.

Authors:  Jia Tai; Junbo Zou; Xiaofei Zhang; Yu Wang; Yulin Liang; Dongyan Guo; Mei Wang; Chunli Cui; Jing Wang; Jiangxue Cheng; Yajun Shi
Journal:  Evid Based Complement Alternat Med       Date:  2019-10-20       Impact factor: 2.629

5.  Upregulation of Transient Receptor Potential Canonical Type 3 Channel via AT1R/TGF-β1/Smad2/3 Induces Atrial Fibrosis in Aging and Spontaneously Hypertensive Rats.

Authors:  Rongfang He; Juan Zhang; Dan Luo; Yiyan Yu; Tangting Chen; Yan Yang; Fengxu Yu; Miaoling Li
Journal:  Oxid Med Cell Longev       Date:  2019-11-23       Impact factor: 6.543

6.  Exosomes Containing LINC00636 Inhibit MAPK1 through the miR-450a-2-3p Overexpression in Human Pericardial Fluid and Improve Cardiac Fibrosis in Patients with Atrial Fibrillation.

Authors:  Langsha Liu; Fanyan Luo; Kaibo Lei
Journal:  Mediators Inflamm       Date:  2021-06-28       Impact factor: 4.711

7.  Direct Activation of TRPC3 Channels by the Antimalarial Agent Artemisinin.

Authors:  Nicole Urban; Michael Schaefer
Journal:  Cells       Date:  2020-01-14       Impact factor: 6.600

Review 8.  Calcium and Heart Failure: How Did We Get Here and Where Are We Going?

Authors:  Natthaphat Siri-Angkul; Behzad Dadfar; Riya Jaleel; Jazna Naushad; Jaseela Parambathazhath; Angelia A Doye; Lai-Hua Xie; Judith K Gwathmey
Journal:  Int J Mol Sci       Date:  2021-07-09       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.